- Health Canada has approved the use of Moderna Inc's MRNA mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose in children six months to 5 years.
- Positive interim results from the Phase 2/3 KidCOVE study, announced in March, showed a robust neutralizing antibody response in the 6-month to 5 years of age group.
- The antibody titers in the pre-specified six-month to 23-month and two to 5 years of age sub-groups met the statistical criteria.
- Related: Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants.
- Preliminary efficacy analysis during the Omicron wave showed similar efficacy estimates against Omicron in the 6-month to 5 years.
- European Medicines Agency added extensive swelling of the vaccinated limb in the EU product information as a side effect of Spikevax.
- Price Action: MRNA shares are down 7.18% at $158.91 during the market session on the last check Thursday.
- Photo by mufidpwt via Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in